Mindstrong Health is a modern company that introduced the concept of detecting neurological conditions using smartphones. Mindstrong Health has managed to raise $14 million to promote its efforts of creating a mobile platform for diagnosing and treating neuropsychiatric disorders. The platform is able to monitor how using smart phones impacts on brain function. The company aims at identifying the digital biomarkers of mood and cognition. These biomarkers include attention, memory, processing speed, and executive roles. The platform uses a person’s typing and scrolling patterns to measure how their brain functions.
The Work Force At Mindstrong
Mindstrong Health has a workforce that is conversant with the situation surrounding the diagnosis and treatment of mental health conditions. The CEO of Foresite Capital, Jim Tananbaum has remarked how the technical vision, collective experience, and leadership of experts involved with the study of neuropsychiatric treatment, will improve the outcomes of patients using innovative and modern health care platforms.
Paul Dagum, CEO of Mindstrong Health, recently stated that his company’s technology offers objective and continuous measurements of a person’s behavior and reasoning in a manner that has never been experienced before. Modern medicine techniques use objective measurements to determine a person’s mental health. However, Dagum argues that measurements of mental health should be subjective. The best strategy for improving the outcomes of people experiencing mental disorders is to device objective strategies like the ones adopted for treating chronic conditions like diabetes and heart disease.
About Jim Tananbaum
Jim Tananbaum established Foresite Capital and is its current CEO. The firm’s has assets worth $1.1 billion. Jim has been in the work of establishing and investing in health care programs for more than 20 years. Prior to the creation of Foresite Capital, Jim had been involved with the establishment of two bio-pharmaceutical companies and two investment companies. Check out LinkedIn to know more.
Jim Tananbaum’s passion for medicine became apparent when he completed his studies at Harvard Medical School and immediately started his own pharmaceutical company. The company came to be known as “GelTex Pharmaceuticals”. The firm brought into the market two drugs that generated a return of under $80 million. Currently, these drugs generate revenue of $ 1 billion. However, GelTex no longer belongs to Jim; he sold it off for $1.6 billion. Jim also founded Theravance Biopharma and Theravance Inc. Combined these companies are valued at $2.75 billion.